Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE VISCOUS versus PRILOCAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE VISCOUS versus PRILOCAINE HYDROCHLORIDE.
LIDOCAINE HYDROCHLORIDE VISCOUS vs PRILOCAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and propagation of action potentials. It also has antiarrhythmic properties (Class Ib) by accelerating repolarization and reducing automaticity in cardiac tissues.
Prilocaine hydrochloride is an amino amide local anesthetic that reversibly blocks sodium channels in nerve cell membranes, inhibiting nerve impulse propagation.
Adult: 15 mL (300 mg) orally every 3 hours, not to exceed 8 doses in 24 hours. Viscous formulation swished and swallowed.
Adults: 4 mg/kg (max 200 mg) via infiltration or nerve block; may repeat after 2 hours with 50% of initial dose.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours (adults); prolonged in heart failure (2.5–4 hours) or hepatic disease (up to 5–7 hours). Context: short t1/2 limits toxic accumulation with topical use.
Terminal half-life: 1.5-2 hours (adults, normal hepatic function). Prolonged in neonates (up to 8-12 hours) due to immature hepatic metabolism and reduced clearance; may cause methemoglobinemia. Hepatic impairment increases half-life.
Renal: ~90% as metabolites (mainly 4-hydroxy-2,6-xylidine and glucuronides), <10% unchanged. Biliary/fecal: minor (<5%).
Renal: ~95% as metabolites (primarily o-toluidine and 4-hydroxy-2-methylaniline) and <5% unchanged. Biliary/fecal: minimal (<2%).
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic